WEsTRA et al., 1991 - Google Patents

Factors determining prolongation of rat heart allograft survival by perioperative injection of donor spleen cells

WEsTRA et al., 1991

Document ID
12615621606130527346
Author
WEsTRA A
PETERSEN A
WILDEvUUR C
PROP J
Publication year
Publication venue
Transplantation

External Links

Snippet

Previously, we have shown that a perioperative injection of donor mononuclear cells in combination with cyclosporine treatment on day 2 after transplantation prolongs heart allograft survival in rats. In this study we determined whether the efficacy of this treatment …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
US7892578B2 (en) Treatment of hematologic disorders
Tutschka et al. Use of cyclosporin A in allogeneic bone marrow transplantation in the rat
McKenzie et al. The effect of donor pretreatment on interstitial dendritic cell content and rat cardiac allograft survival
Santos Bone marrow transplantation in leukemia: Current status
WEsTRA et al. Factors determining prolongation of rat heart allograft survival by perioperative injection of donor spleen cells
van de Mast et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: a self-protective mechanism
Przepiorka et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation
Kamani et al. Bone marrow transplantation; problems and prospects
Tutschka et al. Use of cyclosporin A (CsA) in a rat model of allogeneic marrow transplantation
James et al. Tolerance induction to rat islet allografts by intrathymic inoculation of donor spleen cells
Kolb et al. Bone marrow transplantation in DLA-haploidentical canine littermates: fractionated total body irradiation (FTBI) and in vitro treatment of the marrow graft with anti-T-cell globulin (ATCG)
Rieder et al. Leukocyte transfusions for the modification of host-versus-graft reactions in dogs
Johnsson et al. The immunomodulator LS-2616 (Linomide) more effectively than sensitization of the donor enhances graft-versus-host reaction after small bowel transplantation
Moller et al. Cellular mechanisms underlying differential rejection of sequential heart and lung allografts in rats
van der Kwast et al. Secondary delayed type hypersensitivity to sheep red blood cells in mice: dependence on long-lived memory cells
EP0983074B1 (en) Non-myeloablative tolerogenic treatment
Johnson et al. Donor-specific blood transfusions with stored and fresh blood in a rat heart allograft model
US20010036664A1 (en) L-leucyl-L-leucine methyl ester treatment of donor lypmhocyte infusions in bone marrow transplant patients
Seledtsov et al. Induction of mixed allogeneic chimerism for leukemia
Takiff et al. Low-dose cyclosporine maintenance therapy after immunosuppressive induction in a rat cardiac transplant model
AU2003204277B2 (en) Treatment of hematologic disorders
YOSHIMURA et al. The requirement for the renal transplant to induce allograft unresponsiveness by the combination of extracted histocompatibility antigen and cyclosporine
Storb et al. Engraftment of HLA identical marrow in treatment of severe aplastic anemia: results of 110 consecutive transplants
Parkman Preparation for bone marrow transplantation
Ludwin et al. Prolonged allograft survival resulting from donor pretreatment with phytohemagglutinin-P